Our novel results show that in addition to GFAP, blood biomarkers of neural injury (NfL) and tau (p-tau181) are changed in AxD, particularly those with infantile onset, and should be further examined in the wider context of AxD. This evidence concerns the gene NEFL and Alexander disease.